Porth's Essentials of Pathophysiology, 4e

511

Heart Failure and Circulatory Shock

C h a p t e r 2 0

16. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999;341(17):1276–1283. 17. Chatterjee K. Pathophysiology of systolic and diastolic failure. Med Clin North Am. 2012;96:891–899. 18. Brouwers FB, Hillege HL, van Gist WH, et al. Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved heart failure. Curr Heart Fail Rep. 2012;9:363–368. 19. Redfield M. Heart failure with normal ejection fraction. In: Bonow R, Mann DL, Zipes DP, et al., eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine . 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:586–600. 20. Bortaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670–679. 21. Fletcher L, Thomas D. Congestive heart failure: understanding the pathophysiology and management. J Am Acad Nurse Pract. 2001;13,249–257. 22. McMurray JJV. Systolic heart failure. N Engl J Med. 2010;362(3):228–238. 23. Wu EB, Yu CM. Management of diastolic heart failure: a practical review of pathophysiology and treatment trial data. Int J Clin Pract. 2005;59:1239–1246. 24. Aurigemma GP, Gaasch WH. Diastolic heart failure. N Engl J Med. 2004;351:1095–1105. 25. Haney S, Sur D, Xu Z. Diastolic heart failure: a review and primary care perspective. J Am Board Fam Pract. 2005;18:189–195. 26. Guglin M, Verma S. Right side of heart failure. Heart Fail Rev. 2012;17:511–527. 27. Budev MM, Arroliga AC, Wiedemann HP, et al. Cor pulmonale: an overview. Semin Respir Crit Care Med. 2003;23:233–243. 28. Greenberg B, Kahn AM. Clinical assessment of heart failure. In: Bonow R, Mann DL, Zipes DP, et al., eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine . 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:505–516. 29. Calvin AD, Albuquerque FN, Adachi T, et al. Obstructive sleep apnea and heart failure. Curr Treat Options Cardiovasc Med. 2009;11(6):447–454. 30. Brack T. Cheyne-Stokes respiration in patients with congestive heart failure. Swiss Med Wkly. 2003;133:605–610. 31. Pureza V, Florea VG. Mechanisms for cachexia in heart failure. Curr Heart Fail Rep. 2013;10(4):307–314. 32. Crijns HJ, Tjeerdsma G, DeKam PJ, et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic HF. Eur Heart J. 2000;21:1238–1245. 33. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndrome: current state and framework for future research. Circulation. 2005;112:3958–3968. 34. Mebazaa A, Gheorghliade M, Piña IL. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008;36(1 suppl):S129–S139. 35. Chen HH, Schrier RW. Pathophysiology of volume overload in acute heart failure syndromes. Am J Med. 2006;119(12A):S11–S26. 36. Kale P, Fang JC. Devices in acute heart failure. Crit Care Med. 2008;36(1 suppl):S121–S128. 37. Clerico A, Vittorini S, Passino C. Circulating forms of the B-type natriuretic peptide prohormone: pathophysiologic and clinical considerations. Adv Clin Chem. 2012;58:31–44. 38. Bridges EJ. Hemodynamic monitoring. In: Woods SL, Froelicher ESS, Motzer SU, et al., eds. Cardiac Nursing . 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:478–526. 39. Riegel B, Moser DK, Anker SD, et al. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. American Heart

Association Council on Cardiovascular Nursing; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Nutrition, Physical Activity, and Metabolism; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation. 2009;120(12):1141–1163. 40. Katzung BG. Drugs used in heart failure. In: Katzung BG, Masters SB, Trevor AJ, eds. Basic & Clinical Pharmacology . 12th ed. New York, NY: McGraw-Hill; 2012. 41. Slaughter MS, Pagani FD, Rogers JG. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29:S1–S39. 42. Wheeldon DR. Mechanical circulatory support: state of the art and future perspectives. Perfusion. 2003;8:233–243. 43. Patel ND, Barreiro CJ, Williams JA, et al. Surgical ventricular remodeling for patients with clinically advanced congestive HF and severe left ventricular dysfunction. J Heart Lung Transplant. 2005;24:2202–2210. 44. Thomas S, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in the elderly. Clin Geriatr Med. 2007;23:1–10. 45. Rich MW. Heart failure in older adults. Med Clin North Am. 2006;90:863–885. 46. Schwartz JB, Zipes DP. Cardiovascular disease in the elderly. In: Bonow RO, Mann DL, Zipes DP, et al., eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine . 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:1727–1756. 47. Abdelhafiz AH. Heart failure in older people: causes, diagnosis, and treatment. Age Ageing. 2002;31:29–36. 48. Holmes CL, Walley KR. The evaluation and management of shock. Clin Chest Med. 2003;24:775–789. 49. Graham CA, Parke TRJ. Critical care in the emergency department: shock and circulatory support. Emerg Med J. 2005;22:17–21. 50. Guly HR, Bouamra O, Spiers M, et al. Vital signs and estimated blood loss in patients with major trauma: testing the validity of the ATLS classification of hypovolaemic shock. Resuscitation. 2011;82:556–559. 51. Dutton RP. Current concepts in hemorrhagic shock. Anesthesiol Clin. 2007;25:23–34. 52. Reinhart K, Perner A, Sprung CL, et al. Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med. 2012;3:368–383. 53. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2013;2:CD000567. 54. Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med. 2011;183:847–855. 55. Buerke M, Lemm H, Dietz K. Pathophysiology, diagnosis, and treatment of infarction-related cardiogenic shock. Herz. 2011;36:73–83. 56. Antman EM, Morrow DA. ST-elevation myocardial infarction: management. In: Bonow RO, Mann DL, Zipes DP, et al., eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine . 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:1111–1170. 57. Goldberg RJ, Spencer FA, Gore JM, et al. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation. 2009;119:1211–1219. 58. Abdel-Qadir HM, Ivanov J, Austin PC, et al. Temporal trends in cardiogenic shock treatment and outcomes among Ontario patients with myocardial infarction between 1992 and 2008. Circ Cardiovasc Qual Outcomes. 2011;4:440–447.